“ To Bean or Not to Bean ”: Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens

(MP), a leguminous plant naturally rich in levodopa, has regained attention as both a traditional remedy and a potential therapeutic option for Parkinson's disease (PD). Its appeal is shaped by contrasting contexts: in low- and middle-income countries (LMICs), MP may represent a cost-effective, locally cultivable alternative where access to levodopa-based medications is severely limited; in high-income countries, patients are often drawn to its "natural" label, perceiving it as safer or more holistic than synthetic drugs. Evidence from randomised and open-label clinical trials demonstrates that properly processed MP preparations provide symptomatic benefits comparable to commercial levodopa, though long-term safety data are still scarce. However, despite its natural origin, MP is a potent dopaminergic therapy requiring the same caution as commercially available levodopa-based medications. Overuse and unsupervised self-medication have been associated with dyskinesia, dopamine dysregulation syndrome, and psychiatric complications, while cases of toxicity from improper seed preparation underscore its risks. In our view, a balanced perspective is essential: while MP holds promise as a sustainable therapeutic option in LMICs, its use should remain restricted to clinical trials or neurologist-led protocols until more robust evidence of long-term safety and efficacy emerges.